Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
SURMOUNT-1: Tirzepatide for Obesity The SURMOUNT-1 trial (NEJM, 2022) studied tirzepatide weight loss in 2,539 adults with obesity (without diabetes) over 72 weeks: STEP 1: Semaglutide for Obesity The STEP 1 trial (NEJM, 2021) studied semaglutide 2.4mg in 1,961 adults with obesity (without diabetes) over 68 weeks: Cross-Trial Summary Comparing across trials (with the caveat that indirect comparison has limitations): tirzepatide 15mg produced about 6 percentage points more weight loss than semaglutide 2.4mg over similar timeframes
Molecular mechanisms of IGF-1 mediated muscle hypertrophy
& Zwozdziak, B
its the first twincretin to hit the market
What types of drugs are compounded most often
Cons of GLP-1s: Potential side effects, high cost, and the need for continuous use
